Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, today announced upcoming presentations at the 67th American Society of Hematology (ASH) Annual Meeting being held December 6-9, 2025, in Orlando, Florida.
Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body.
The oral and poster presentations will highlight data supporting Orna’s leading in vivo CAR programs to target and treat a broad range of B-cell driven autoimmune diseases and its anti-BCMA platform to selectively deplete plasma cells.
“We are excited to share new data at ASH from our NHP studies for our CD19 and BCMA panCAR programs,” said Joseph Bolen, Ph.D., Chief Executive Officer of Orna Therapeutics. “Data to be presented continues to demonstrate the best-in-class nature of our in vivo CAR platform in NHP for both our anti-CD19 and our anti-BCMA programs. As we look ahead, we have completed our pre-clinical package for anti-CD19 and will be submitting our Clinical Trial Application this Quarter.”
Oral Presentation details:
Title: In Vivo pan CAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Speaker: Isin Dalkilic-Liddle, Ph.D., VP Discovery Sciences, Orna Therapeutics
Date/Time: Saturday, December 6, 2025, 9:45 AM – 10:00 AM ET
Session Name: CAR-T Cell Therapies: Basic and Translational: In vivo CAR-T cell platforms and resistance mechanisms
Location: OCCC – Sunburst Room (W340)
Poster Presentation details:
Title: In Vivo pan CAR Therapy Utilizing Circular RNA for Treatment of Multiple Myeloma
Speaker: Rebecca Silver, Ph.D., Pr. Scientist, Orna Therapeutics
Date/Time: Sunday, December 7, 2025, 6:00 PM – 8:00 PM ET
Session Name: CAR-T Cell Therapies: Basic and Translational: Poster II
Location: OCCC – West Halls B3-B4
By leveraging its leading oRNA technology and best-in-class LNP delivery, Orna’s in vivo oRNA panCAR therapies hold the potential to benefit patients across multiple B-cell-driven autoimmune diseases. New data to be presented at ASH will highlight Orna’s oRNA panCAR platform’s ability to generate deep, sustained B cell depletion in non-human primates across multiple doses and therapeutic areas.
__
Featured image: New Orleans, LA – ASH 2022- Attendees during General Views at the American Society of Hematology 64th Annual Meeting at the Georgia World Congress Center. Photo courtesy © 2022 ASH/Zach Boyden-Holmes. Used with permission.
DOI
